Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a substantial global disease burden. This study aims to elucidate the role of intestinal NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome in the gut-liver axis and provide novel insights for potential therapeutic targets. Methods Mice were fed with a methionine-choline deficient (MCD) diet for four weeks to induce MASLD models. Nlrp3fl/fl and Vil1creNlrp3fl/fl mice, with a specific knockout of NLRP3 in intestinal epithelial cells, were housed either separately or together to establish models for MASLD. Liver and intestinal tissues were collected for the assessment of hepatic steatosis, inflammation, fibrosis, and integrity of the intestinal mucosal barrier, while fecal microbiota composition was analyzed using 16S rDNA sequencing. The in vivo effects of intragastric butyrate were evaluated using Vil1creNlrp3fl/fl-MCD mice. Results Wild-type (WT)-MCD mice exhibited exacerbated hepatic steatosis and reduced intestinal NLRP3 mRNA expression compared to WT mice fed with a methionine-choline sufficient (MCS) diet, suggesting a protective role of intestinal NLRP3. The Vil1creNlrp3fl/fl-MCD vs. Nlrp3fl/fl-MCD mice exhibited elevated hepatic lipid deposition and increased expression of α-SMA. Additionally, they displayed compromised intestinal mucosal barrier function characterized by shortened villi, reduced goblet cell count, and decreased expression of Reg3a and Cldn7. The co-housed Vil1creNlrp3fl/fl-MCD with Nlrp3fl/fl-MCD mice showed a significantly ameliorated liver phenotype, characterized by reduced steatosis and fibrosis, in comparison with separately-housed Vil1creNlrp3fl/fl-MCD mice. This improvement was accompanied by an increased abundance of Faecalibaculum rodentium, a well-known butyrate producer. The in vivo administration of butyrate significantly ameliorated hepatic lipid accumulation and fibrogenesis in Vil1creNlrp3fl/fl-MCD mice. Further, a significant upregulation of activating protein-1 (AP-1) mRNA levels was observed in the liver of Vil1creNlrp3fl/fl-MCD mice, while both co-housed Vil1creNlrp3fl/fl-MCD mice and butyrate administration significantly exhibited downregulated expression of AP-1. Conclusions Deletion of NLRP3 in intestinal epithelial cells leads to a reduction in the abundance of Faecalibaculum rodentium and butyrate production, resulting in the upregulation of hepatic AP-1 expression, thereby exacerbating MASLD.

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

Critical role for the NLRP3 inflammasome in colitis and colitis associated colorectal cancer (47.9)

Glyburide Suppresses Inflammation-Related Colorectal Tumorigenesis Through Inhibition of NLRP3 Inflammasome

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease

Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes

NLRP3 Inflammasome and Inflammatory Bowel Disease

NLRP3 inflammasome in colitis and colitis-associated colorectal cancer

Suppression of Glucagon-Like Peptide-1 Release by Inhibition of Intestinal NLRP3 Inflammasome Activation in Asc–/– and Nlrp3–/– Mice

NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity

Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development.

CCN3 aggravates intestinal inflammation in inflammatory colitis through regulating NLRP3 inflammasome in macrophages

Jmjd3 Regulates Inflammasome Activation and Aggravates DSS‐induced Colitis in Mice

Canonical Stimulation of the NLRP3 Inflammasome by Fungal Antigens Links Innate and Adaptive B-Lymphocyte Responses by Modulating IL-1β and IgM Production

Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis